Organon & Co
About: Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Employees: 10,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
25% more call options, than puts
Call options by funds: $31.7M | Put options by funds: $25.4M
0% less repeat investments, than reductions
Existing positions increased: 220 | Existing positions reduced: 221
2% less capital invested
Capital invested by funds: $3.07B [Q4 2024] → $3.01B (-$62.7M) [Q1 2025]
9% less first-time investments, than exits
New positions opened: 86 | Existing positions closed: 94
1.69% less ownership
Funds ownership: 79.84% [Q4 2024] → 78.14% (-1.69%) [Q1 2025]
3% less funds holding
Funds holding: 720 [Q4 2024] → 698 (-22) [Q1 2025]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 4 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Piper Sandler David Amsellem | 75%upside $18 | Overweight Maintained | 15 May 2025 |
Morgan Stanley Terence Flynn | 3%downside $10 | Equal-Weight Maintained | 5 May 2025 |
Financial journalist opinion
Based on 137 articles about OGN published over the past 30 days
